Dermatitis News and Research

Latest Dermatitis News and Research

Nasdaq Stock Market issues noncompliance notice to PhotoMedex

PhotoMedex, Inc. (Nasdaq:PHMD) (the “Company”) announced today that it received notification from The Nasdaq Stock Market (“Nasdaq”) on September 15, 2009 that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq’s Global Market exchange under Nasdaq Marketplace Rule 4450(a)(5) (the “Rule”).

19 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

PhotoMedex unveils Neova DNA Repair Factor Nourishing Lotion

PhotoMedex, Inc., a leading provider of advanced dermatology, clinical skincare and medical laser products, today announced Neova DNA Repair Factor Nourishing Lotion, the newest addition to its renowned Neova brand of skin and hair products.

16 Sep 2009

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing.

15 Sep 2009

Internet marketing program from AVVH

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced today the launch of a major Internet marketing program.

14 Sep 2009

Pergamum to develop Karolinska dermatology and wound healing companies

Pergamum AB has announced its formation; Pergamum will commercialize the Karolinska Development dermatology and wound healing interests, and create a broad-based therapeutic company in its focus areas.

11 Sep 2009

Karolinska Development announces formation of Pergamum AB business unit

Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.

10 Sep 2009

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health (“NIH”) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.

9 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

Preliminary lab results of SHBAN hand sanitizer solution announced

BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has received preliminary independent clinical testing of its patented SHBAN™ Hand Sanitizer Solution to demonstrate it kills the H1N1 (Swine) Influenza A virus.

3 Sep 2009

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the “Company”), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive evaluation and option to license agreement (the "Agreement”) with a global, multi-billion dollar healthcare company covering the use of the Company's CeraShield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections.

1 Sep 2009

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.

26 Aug 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.

18 Aug 2009

Researchers unlock mystery of potentially fatal reaction to smallpox vaccine

Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine.

25 May 2009

Researchers look at eczema asthma link

Many young children who get a severe skin rash develop asthma months or years later. Doctors call the progression from eczema, or atopic dermatitis, to breathing problems the atopic march. In the May 2009 issue of PLoS Biology, scientists at Washington University School of Medicine in St. Louis report another step taken towards understanding the process of atopic march.

18 May 2009

Household bleach has a surprising new role: an effective treatment for kids' chronic eczema

Researchers from the Northwestern University Feinberg School of Medicine have discovered powerful relief in the form of diluted beach baths. It's a cheap, simple and safe treatment that drastically improves the rash as well as reduces flare-ups of eczema, which affects 17 percent of school-age children.

27 Apr 2009

Review of homeopathic medicines in easing cancer therapy symptoms

Drugs and radiotherapy given for cancer can cause unpleasant side effects such as nausea and vomiting, mouth sores, dermatitis, and menopausal symptoms.

14 Apr 2009

Dermatitis News and Research

Latest Dermatitis News and Research

Nasdaq Stock Market issues noncompliance notice to PhotoMedex

Amgen to present its four Phase 3 clinical trial results

PhotoMedex unveils Neova DNA Repair Factor Nourishing Lotion

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Internet marketing program from AVVH

Pergamum to develop Karolinska dermatology and wound healing companies

Karolinska Development announces formation of Pergamum AB business unit

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Results of Phase 2 rheumatoid arthritis clinical trial announced

Preliminary lab results of SHBAN hand sanitizer solution announced

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Ceragenix Pharmaceuticals updates license agreement covering antimicrobial technology use

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Researchers unlock mystery of potentially fatal reaction to smallpox vaccine

Researchers look at eczema asthma link

Household bleach has a surprising new role: an effective treatment for kids' chronic eczema

Review of homeopathic medicines in easing cancer therapy symptoms

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Dermatitis News and Research

Latest Dermatitis News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in